Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

doi:10.1084/jem.141.3.697

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Askenase, P. W.
	Articles by Gershon, R. K.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Askenase, P. W.
	Articles by Gershon, R. K.


Social Bookmarking

	What's this?

ARTICLES

Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses

PW Askenase, BJ Hayden and RK Gershon

Mice immunized with more SRBC than are required to produce optimal delayed-type hypersensitivity reactions, developed good antibody responses and poor delayed foot pad reactions. Cyclophosphamide treatment in low doses (20 mg/kg) before immunization, augmented the delayed-type hypersensitivity without affecting antibody responses. Cyclophosphamide did not augment delayed responses to optimal doses of SRBC (0.01%), but did augment the delayed hypersensitivity response of mice immunized with a suboptimal antigen dose (0.001%); which produced no detectable antibody response with or without cyclophosphamide pretreatment. These results suggest that antibody feedback is not the sole regulator of delayed reactions; the possibility that suppressor T cells may also be involved is discussed.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Menard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jese, G., Lemonnier, F., Zitvogel, L. (2006). Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.. J. Immunol. 176: 2722-2729 [Abstract] [Full Text]
Deruytter, N., Boulard, O., Garchon, H.-J. (2004). Mapping Non-Class II H2-Linked Loci for Type 1 Diabetes in Nonobese Diabetic Mice. Diabetes 53: 3323-3327 [Abstract] [Full Text]
Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L., Cerundolo, V. (2003). Synergistic Effect of Metronomic Dosing of Cyclophosphamide Combined with Specific Antitumor Immunotherapy in a Murine Melanoma Model. Cancer Res. 63: 8408-8413 [Abstract] [Full Text]
Haque, R, Bin-Hafeez, B, Ahmad, I, Parvez, S, Pandey, S, Raisuddin, S (2001). Protective effects of Emblica officinalis Gaertn. in cyclophosphamide-treated mice. Hum Exp Toxicol 20: 643-650 [Abstract]
Herbelin, A., Gombert, J.-M., Lepault, F., Bach, J.-F., Chatenoud, L. (1998). Mature Mainstream TCR{alpha}{beta}+CD4+ Thymocytes Expressing L-Selectin Mediate ""Active Tolerance"" in the Nonobese Diabetic Mouse. J. Immunol. 161: 2620-2628 [Abstract] [Full Text]
Tsuji, R. F., Geba, G. P., Wang, Y., Kawamoto, K., Matis, L. A., Askenase, P. W. (1997). Required Early Complement Activation in Contact Sensitivity with Generation of Local C5-dependent Chemotactic Activity, and Late T Cell Interferon gamma : A Possible Initiating Role of B Cells. J. Exp. Med. 186: 1015-1026 [Abstract] [Full Text]